Biochemical Modulation of Aracytidine (Ara-C) Effects by GTI-2040, a Ribonucleotide Reductase Inhibitor, in K562 Human Leukemia Cells

GTI-2040 is a potent antisense to the M2 subunit of the ribonucleotide reductase (RNR), an enzyme involved in the de novo synthesis of nucleoside triphosphates. We hypothesized that combination of GTI-2040 with the cytarabine (Ara-C) could result in an enhanced cytotoxic effect with perturbed intracellular deoxynucleotide/nucleotide (dNTP/NTP) pools including Ara-C triphosphate (Ara-CTP). This study aims to provide a direct experimental support of this hypothesis by monitoring the biochemical modulation effects, intracellular levels of Ara-CTP, dNTPs/NTPs following the combination treatment of Ara-C, and GTI-2040 in K562 human leukemia cells. GTI-2040 was introduced into cells via electroporation. A hybridization–ligation ELISA was used to quantify intracellular GTI-2040 concentrations. Real-time PCR and Western blot methods were used to measure the RNR M2 mRNA and protein levels, respectively. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt assay was used to measure the cytotoxicity following various drug treatments. A non-radioactive HPLC-UV method was used for measuring the intracellular Ara-CTP, while a LC-MS/MS method was used to quantify intracellular dNTP/NTP pools. GTI-2040 was found to downregulate M2 mRNA and protein levels in a dose-dependent manner and showed significant decrease in dNTP but not NTP pool. When combining GTI-2040 with Ara-C, a synergistic cytotoxicity was observed with no further change in dNTP/NTP pools. Importantly, pretreatment of K562 cells with GTI-2040 was found to increase Ara-CTP level for the first time, and this effect may be due to inhibition of RNR by GTI-2040. This finding provides a laboratory justification for the current phase I/II evaluation of GTI-2040 in combination with Ara-C in patients with acute myeloid leukemia.

[1]  R. Willemze,et al.  High dose cytosine arabinoside in the management of refractory acute leukaemia. , 2009, Scandinavian journal of haematology.

[2]  M. Grever,et al.  Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia , 2008, Clinical Cancer Research.

[3]  Fangxia Wang,et al.  Combination chemotherapy with low‐dose cytarabine, homoharringtonine, and granulocyte colony‐stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia , 2008, American journal of hematology.

[4]  Jian-yong Li,et al.  Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. , 2007, Leukemia research.

[5]  H. Arai,et al.  Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. , 2007, Anticancer research.

[6]  M. Grever,et al.  A LC-MS/MS Method for the Analysis of Intracellular Nucleoside Triphosphate Levels , 2009, Pharmaceutical Research.

[7]  G. Marcucci,et al.  A Specific Picomolar Hybridization-Based ELISA Assay for the Determination of Phosphorothioate Oligonucleotides in Plasma and Cellular Matrices , 2006, Pharmaceutical Research.

[8]  R. Schilsky,et al.  A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Djurovic,et al.  Electroporation by nucleofector is the best nonviral transfection technique in human endothelial and smooth muscle cells , 2005, Genetic vaccines and therapy.

[10]  V. Gandhi,et al.  Biochemical modulation of cytarabine triphosphate by clofarabine , 2005, Cancer Chemotherapy and Pharmacology.

[11]  T. Szekeres,et al.  Amidox, an Inhibitor of Ribonucleotide Reductase, Potentiates the Action of Ara‐C in HL‐60 Human Promyelocytic Leukemia Cells , 2004, Nucleosides, Nucleotides & Nucleic Acids.

[12]  M. Kolberg,et al.  Structure, function, and mechanism of ribonucleotide reductases. , 2004, Biochimica et biophysica acta.

[13]  C. Galmarini,et al.  Problems Related to Resistance to Cytarabine in Acute Myeloid Leukemia , 2004, Leukemia & lymphoma.

[14]  G. Peters,et al.  The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. , 2004, Blood.

[15]  B. Smith,et al.  Ribonucleotide reductase: an old target with new potential. , 2003, Leukemia research.

[16]  V. Lam,et al.  GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. , 2003, Cancer research.

[17]  Y. Ravindranath.  Recent advances in pediatric acute lymphoblastic and myeloid leukemia , 2003, Current opinion in oncology.

[18]  T. Szekeres,et al.  Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells. , 2002, Biochemical pharmacology.

[19]  A. V. van Kuilenburg,et al.  Cyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of 1‐β‐D‐arabinofuranosyl cytosine in a human T‐lymphoblastic cell line , 2002, International journal of cancer.

[20]  E. Estey.  Therapeutic options for acute myelogenous leukemia , 2001, Cancer.

[21]  W. Hiddemann,et al.  Successful modulation of high‐dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine , 2000, British journal of haematology.

[22]  Wan Ariffin Bin Abdullah,et al.  Med Pediatr Oncol , 1999 .

[23]  V. Avramis,et al.  Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. , 1998, Medical and pediatric oncology.

[24]  M. Fontecave.  Ribonucleotide reductases and radical reactions , 1998, Cellular and Molecular Life Sciences CMLS.

[25]  G. Nocentini,et al.  Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. , 1996, Critical reviews in oncology/hematology.

[26]  F. Calderazzo,et al.  Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Richel,et al.  Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway , 1992, Annals of Hematology.

[28]  K. Bhalla,et al.  Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells. , 1991, Blood.

[29]  J. White,et al.  Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. , 1991, Seminars in hematology.

[30]  W. Plunkett,et al.  Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. , 1989, Blood.

[31]  M. Krailo,et al.  Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. , 1987, Cancer research.

[32]  E. Estey,et al.  Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. , 1987, Leukemia.

[33]  E. Estey,et al.  Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia. , 1987, Seminars in oncology.

[34]  Jan Liliemark,et al.  Relationship of 1-β-d-Arabinofuranosylcytosine in Plasma to 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Levels in Leukemic Cells during Treatment with High-Dose 1-β-d-Arabinofuranosylcytosine , 1985 .

[35]  C. Spurr,et al.  Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. , 1984, Blood.

[36]  P. Reichard,et al.  Ribonucleotide reductase--a radical enzyme. , 1983, Science.

[37]  H. Löffler,et al.  Clinical results and pharmacokinetics of high‐dose cytosine arabinoside (HD ARA‐C) , 1982, Cancer.

[38]  W. Plunkett,et al.  Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. , 1980, Cancer research.

[39]  D. Abraham,et al.  Metabolism and cytotoxicity of 5-azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia cells and their enhancement by preincubation with pyrazofurin. , 1978, Cancer research.

[40]  H. Morris,et al.  Increased CTP synthetase activity in cancer cells , 1978, Nature.

[41]  P. Calabresi,et al.  Biochemical and pharmacological studies with 1-beta-D-arabinofuranosylcytosine in man. , 1966, Biochemical pharmacology.

[42]  X. Wei.  Pharmacokinetics, pharmacodynamics and metabolism of GTI-2040, a phosphorothioate oligonucleotide targeting R2 subunit of ribonucleotide reductase , 2006 .

[43]  Li-ming Wang,et al.  The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology , 2004, Cancer Chemotherapy and Pharmacology.

[44]  A. V. van Kuilenburg,et al.  Cyclopentenyl cytosine increases the phosphorylation and incorporation into dna of arabinofu-ranosyl cytosine in a myeloid leukemic cell-line. , 2000, Advances in experimental medicine and biology.

[45]  P. Reichard,et al.  Ribonucleotide reductases. , 1998, Annual review of biochemistry.

[46]  E. Estey,et al.  Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. , 1996, Blood.

[47]  E. Estey,et al.  Modulation of arabinosylcytosine metabolism during leukemia therapy. , 1994, Advances in experimental medicine and biology.

[48]  J. G. Cory.  Ribonucleotide reductase as a chemotherapeutic target. , 1988, Advances in enzyme regulation.

[49]  R. Schilsky,et al.  Simultaneous determination of cytosine arabinoside, its nucleotides and metabolites by ion-pair high-performance liquid chromatography. , 1985, Journal of chromatography.

[50]  W. Plunkett,et al.  Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. , 1985, Cancer research.

[51]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.